BET inhibition, an epigenetic pathway: How could BET inhibition modulate atherothrombotic risk?

10' education - Sep. 30, 2019 - Prof. Wouter Jukema - Leiden, The Netherlands

Video navigation menu

What is epigenetics? 1:16
BET proteins as potential therapeutic targets 3:56
The BET inhibitor apabetalone can potentially impact CVD 6:56
Clinical trials with apabetalone 9:03

Educational information

This lecture by prof. Wouter Jukema was part of an accredited symposium "Epigenetics: A new pathway to tackle residual risk?" held during ESC 2019 in Paris, France.

Faculty

Wouter Jukema, Professor of Cardiology, Leiden University Medical Center, Leiden, The Netherlands

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

Funding

Funding for this educational program was provided by an unrestricted educational grant from Resverlogix.

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.